Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で50.69%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 36.31Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 36.31Mです。
割安
同社の最新のPEは-0.98で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は253.46K株で、前四半期比で57.72%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.98です。